MedTrace Logo

Evolve China PMCF Study

NCT06368622 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-03-30

No results posted yet for this study

Summary

A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.

Conditions

  • Intracranial Aneurysm

Interventions

DEVICE

Surpass Evolve Flow Diverter System

Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms

Sponsors & Collaborators

  • Stryker (Beijing) Healthcare Products Co., Ltd

    collaborator INDUSTRY

  • Stryker Neurovascular

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2027-11-30
Completion
2031-08-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06368622 on ClinicalTrials.gov